Clinical Trials Logo

Filter by:
NCT ID: NCT06008431 Not yet recruiting - Fall Clinical Trials

Non-invasive Brain Stimulation to Improve Unsteady Gait in Older Adults (StimGait)

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Walking is a complex and continuous task that entails repetitive motions of the body. Relatively high gait variability sensitively predicts falls and cognitive decline in older adults. Previous work has identified an unique brain network relationship linked to gait variability and its relevant cognitive function (i.e., sustained attention). This project aims to develop a non-invasive brain stimulation montage designed to modulate the shared brain networks dynamics and to demonstrate its effects on resting state functional connectivity, gait and cognitive performance in older adults at risk for falls.

NCT ID: NCT06008275 Not yet recruiting - Breast Cancer Clinical Trials

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Start date: November 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.

NCT ID: NCT06007911 Not yet recruiting - Relapsed Adult AML Clinical Trials

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 15, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label phase I study designed to evaluate the safety of venetoclax-navitoclax with cladribine-based salvage therapy.

NCT ID: NCT06007417 Not yet recruiting - GHD Clinical Trials

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

ELEVATE
Start date: December 1, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.

NCT ID: NCT06007352 Not yet recruiting - Sepsis Clinical Trials

Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate whether the use of gentamicin-based irrigation fluid during ureteroscopy decreases the risk of UTIs and other post-operative infections after surgery.

NCT ID: NCT06006923 Not yet recruiting - Clinical trials for MSI-H Colorectal Cancer

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.

NCT ID: NCT06006182 Not yet recruiting - Healthy People Clinical Trials

The Effects of Freeze-Dried Whole Grape Powder on Chronic Disease and Cardiovascular Risk Factors-a Pilot Study

Start date: August 27, 2023
Phase: N/A
Study type: Interventional

Cardiovascular disease (CVD) is responsible for 1 out of every 5 deaths, is the number one killer of Americans, killing about 700K US adults per year (1). Our proposed research is a clinical trial that will determine the effects of feeding California freeze-dried grapes (which are directly comparable to fresh table grapes), on cardiovascular and chronic disease risk factors, namely, blood glucose and lipids (total cholesterol, LDL, HDL, and triacylglycerides), electrolyte and blood indicators (such as sodium, calcium, potassium, etc.), c-reactive protein (hs-CRP) and tumor necrosis factor alpha (TNF-alpha) (measures of inflammation and CVD risk), body composition (body weight, body fat percentage, lean tissue weight, body water amount and Kcal requirement to maintain body composition status), and blood pressure (BP) in 30 adults. The investigators will test satiety and hunger to see if grape antioxidants decrease both, implying that there will be a decrease in caloric intake and result in body composition improvements.

NCT ID: NCT06005051 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Prediabetes Stratification by Multi-omics Profile After Food Intake

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

1 in 3 adults have prediabetes in the United States, and many of them will eventually develop diabetes, which has significant public health and economic costs. However, type 2 diabetes (T2D) and prediabetes are heterogeneous groups with different pathological mechanisms, dysfunctions in different processes, and varied disease trajectories. Patient stratifications into subtypes and personalized nutrition interventions are highly needed but not yet available. Metabolic responses (e.g., glucose excursion) after food intake provide a direct observation of personal metabolic control and its association with T2D. The investigators hope to learn how prediabetes and type 2 diabetes evolve, and specifically what food or exercise can do to mitigate blood sugar response.

NCT ID: NCT06003712 Not yet recruiting - Quality of Life Clinical Trials

Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI)

Start date: August 31, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if practicing mindfulness breathing exercises has an effect on the overall health of persons with SCI

NCT ID: NCT06003192 Not yet recruiting - HIV Infections Clinical Trials

Screen to Prevent: Using Digital Health to Improve HIV Screening and Prevention

S2P
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

The goal of this interrupted time series quasi-experimental design study is to implement universal opt- out HIV testing and linkage to HIV preventive care in 15-21 year old adolescents visiting the pediatric emergency department (ED). The main question[s] it aims to answer are: 1. What is the uptake, reach and effectiveness of universally offered, opt-out HIV screening across pediatric EDs after implementing an adapted version of a tablet-based screening process? 2. What is the successful linkage to comprehensive HIV pre-exposure prophylaxis (PrEP) care using a novel, digital health platform? Participants will 1. Complete the previously developed and validated computerized sexual health screen (cSHS) containing questions regarding their personal sexual health history 2. Have the opportunity to opt-out of clinician-ordered HIV testing 3. Patients meeting CDC criteria for HIV PrEP will be given the opportunity to enroll in the digital health PrEP linkage platform and followed for 3 months after enrollment.